Johnson & Johnson’s MedTech Division posts solid Q1 growth

J&J reports positive results: ©Yanina - stock.adobe.com

Johnson & Johnson’s $8 billion MedTech segment delivered steady gains in the first quarter of 2025, helping to power the company’s overall performance as it leans into innovation in digital surgery and cardiovascular care.

In its earnings report Tuesday, Johnson & Johnson (NYSE: JNJ) said MedTech worldwide operational sales grew 4.1% in the quarter, reaching $8.02 billion. The segment saw particular strength in cardiovascular products, led by the Abiomed business, as well as wound closure offerings in general surgery. These gains were partially offset by weaker results in orthopaedics, specifically in spine and sports categories.

“Johnson & Johnson’s diversified business model uniquely positions us to navigate challenges while delivering on our financial commitments, advancing an innovative pipeline and creating long-term, sustainable value for shareholders,” said Joe Wolk, executive vice president and chief financial officer, Johnson & Johnson, in a statement. “Our solid results and strong financial foundation enable us to invest for the future, bolster our portfolio and return capital to our shareholders, as evidenced by today’s announcement of our 63rd consecutive year of dividend increases.”

Overall, Johnson & Johnson reported $21.9 billion in total sales for the quarter, a 2.4% increase year-over-year. Adjusted operational sales grew 3.3% after excluding currency and acquisition impacts. Net earnings surged to $11 billion, though that figure was boosted by non-recurring items. On an adjusted basis, earnings per share rose 2.2% to $2.77.

The company reaffirmed its 2025 full-year guidance, projecting operational sales growth between 3.3% and 4.3% and adjusted earnings per share in the range of $10.50 to $10.70.

“The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, chairman and CEO, Johnson & Johnson, in a statement. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.”